Bruker Gains on NanoString Deal

Bruker Corporation (NASDAQ: BRKR) price move into positive territory Monday, on word it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis.

Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString's business, including the nCounter(R), GeoMx(R), CosMxTM and AtoMxTM product lines, for approximately $392.6 million in cash, and the assumption of certain liabilities. In 2023, NanoString generated revenues of approximately $168 million.

Last Friday, the transaction was approved under a court-supervised Chapter 11 sale process pursuant to Section 363 of the U.S. Bankruptcy Code, and it is expected to close in the second quarter of 2024, subject to customary closing conditions.

NanoString is a provider of life science tools for discovery and translational research with leading solutions for spatial transcriptomics and gene expression analysis. For over 15 years, and with over 7,000 peer-reviewed publications, scientists and medical researchers have relied on NanoString's pioneering instruments to advance biological, translational and clinical disease research.

Bruker expects to fund the acquisition with cash on hand and established debt instruments. Following the closing, the NanoString business will become part of the Bruker Spatial Biology business.

BRKR shares advanced 24 cents to $78.00.

• About Us
• Contact Us
• Advertise
• License Our Content
• Jobs
• Disclaimer
• Privacy Policy

Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks

MENAFN22042024000212011056ID1108123542

COMTEX_451259233/2604/2024-04-22T22:40:15